梗阻性肥厚型心肌病运动耐量的研究进展

原艺铭; 王静; 李若暄; 拓胜军; 刘丽文

doi:10.13201/j.issn.1001-1439.2024.11.014

梗阻性肥厚型心肌病运动耐量的研究进展

- 解放军空军军医大学第一附属医院(西京医院)超声医学科解放军空军军医大学第一附属医院(西京医院)肥厚型心肌病国际合作中心陕西省肥厚型心肌病多学科会诊中心西京医院肥厚型心肌病多学科诊治与遗传咨询中心(西安，710032)
基金项目:
国家自然科学基金(No：82071932、82230065、82272009)；陕西省重点研发计划(No：2022KW-32)；军队装备重点课题(No：KJ20191A050284)；空军军医大学凌云计划人才扶持计划(No：2020lyihllw)

详细信息

通讯作者: 刘丽文，E-mail：liuliwen@fmmu.edu.cn

中图分类号: R542.2

收稿日期: 2024-04-16

刊出日期: 2024-11-13

Research progress on influencing factors of exercise capacity of hypertrophic obstructive cardiomyopathy

- Department of Ultrasound, the First Affiliated Hospital of Air Force Medical University, Xijng Hospital; Hypertrophic Cardiomyopathy International Cooperation Center, the First Affiliated Hospital of Air Force Medical University, Xijing Hospital; Multidisciplinary Consultation Center of Hypertrophic Cardiomyopathy, Shaanxi Province; Multidisciplinary Clinic and Genetic Counseling Center of Hypertrophic Cardiomyopathy, Xijing Hospital, Xi'an, 710032, China

More Information

Corresponding author: LIU Liwen, E-mail: liuliwen@fmmu.edu.cn

Received Date: 16 April 2024

Publish Date: 13 November 2024

摘要

摘要: 运动耐量下降是梗阻性肥厚型心肌病(HOCM)的重要症状之一，是许多患者就诊时的主要临床表现，严重限制患者的日常活动，影响其生活质量，也是不良心血管事件的独立预测因素。探究运动耐量降低的影响因素，进行早期个体化干预和治疗，可显著改善此类患者的预后。本文综述HOCM运动耐量降低的指标、影响因素及改善方法。
- 梗阻性肥厚型心肌病 /
- 运动耐量 /
- 影响因素
Abstract: Decreased exercise tolerance is a significant symptom of obstructive hypertrophic cardiomyopathy (HOCM) and is often the primary complaint of many patients seeking medical consultation. It severely restricts their daily activities, significantly impacts quality of life, and serves as an independent predictor of adverse cardiovascular events. A comprehensive understanding of the factors contributing to reduced exercise tolerance in HOCM, along with the implementation early personalized interventions and treatments, can significantly improve patient prognosis. This article reviews the specific factors that influence reduced exercise tolerance in HOCM.
- hypertrophic obstructive cardiomyopathy /
- exercise tolerance /
- influencing factors

HTML全文

参考文献(57)

[1]	Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2024, 149(23): e1239-e1311.
[2]	国家心血管病中心心肌病专科联盟, 中国医疗保健国际交流促进会心血管病精准医学分会"中国成人肥厚型心肌病诊断与治疗指南2023"专家组, 宋雷, 等. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志, 2023, 38(1): 1-33.
[3]	Hwang JW, Lee SC, Kim D, et al. Determinants of Exercise Capacity in Patients With Hypertrophic Cardiomyopathy[J]. J Korean Med Sci, 2022, 37(8): e62. doi: 10.3346/jkms.2022.37.e62
[4]	Su Y, Peng Q, Yin L, et al. Evaluation of Exercise Tolerance in Non-obstructive Hypertrophic Cardiomyopathy With Myocardial Work and Peak Strain Dispersion by Speckle-Tracking Echocardiography[J]. Front Cardiovasc Med, 2022, 9: 927671. doi: 10.3389/fcvm.2022.927671
[5]	Ghiselli L, Marchi A, Fumagalli C, et al. Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy[J]. Eur J Prev Cardiol, 2020, 27(17): 1821-1831. doi: 10.1177/2047487319886961
[6]	中华医学会心血管病学分会, 中国康复医学会心肺预防与康复专业委员会, 中华心血管病杂志编辑委员会. 六分钟步行试验临床规范应用中国专家共识[J]. 中华心血管病杂志, 2022, 50(5): 432-442. doi: 10.3760/cma.j.cn112148-20211206-01054
[7]	Smith JR, Medina-Inojosa JR, Layrisse V, et al. Predictors of Exercise Capacity in Patients with Hypertrophic Obstructive Cardiomyopathy[J]. J Clin Med, 2018, 7(11): 447. doi: 10.3390/jcm7110447
[8]	王东, 陈志国, 吴桂鑫, 等. 心功能分级与肥厚型心肌病预后的相关性分析[J]. 中国分子心脏病学杂志, 2016, 16(3): 1744-1747.
[9]	胡小莹, 孙兴国, 乔树宾, 等. 肥厚型心肌病患者运动血压反应异常的两类表现及其相关因素分析[J]. 中国应用生理学杂志, 2021, 37(1): 27-33.
[10]	胡小莹, 乔树宾, 孙兴国, 等. 肥厚型心肌病患者的心肺功能评估和相关因素研究[J]. 中国循环杂志, 2021, 36(4): 372-378. doi: 10.3969/j.issn.1000-3614.2021.04.009
[11]	中华医学会心血管病学分会, 中国康复医学会心肺预防与康复专业委员会, 中华心血管病杂志编辑委员会. 心肺运动试验临床规范应用中国专家共识[J]. 中华心血管病杂志, 2022, 50(10): 973-986. doi: 10.3760/cma.j.cn112148-20220316-00180
[12]	吴小朋, 李一丹, 吕秀章. 运动负荷超声心动图在肥厚型心肌病中的应用价值[J]. 中华医学杂志, 2018, 98(44): 3627-3629. doi: 10.3760/cma.j.issn.0376-2491.2018.44.018
[13]	Arabadjian M, Yu G, Vorderstrasse A, et al. Quality of life and physical functioning in black and white adults with hypertrophic cardiomyopathy[J]. Heart Lung, 2022, 56: 142-147. doi: 10.1016/j.hrtlng.2022.07.001
[14]	Wu XP, Li YD, Zhang M, et al. Impaired left ventricular mechanics and functional reserve are associated with reduced exercise capacity in patients with hypertrophic cardiomyopathy[J]. Echocardiography, 2019, 36(2): 266-275. doi: 10.1111/echo.14241
[15]	Sorensen LL, Pinheiro A, Dimaano VL, et al. Comparison of Clinical Features in Blacks Versus Whites With Hypertrophic Cardiomyopathy[J]. Am J Cardiol, 2016, 117(11): 1815-1820. doi: 10.1016/j.amjcard.2016.03.017
[16]	Zhou M, Ta S, Hahn RT, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy[J]. JAMA Cardiol, 2022, 7(5): 529-538. doi: 10.1001/jamacardio.2022.0259
[17]	Ta S, Li J, Hsi DH, et al. Percutaneous intramyocardial septal radiofrequency ablation after 5-year follow-up[J]. Heart, 2024, 110(11): 792-799. doi: 10.1136/heartjnl-2023-323606
[18]	梁思颖, 蒲朝霞. 梗阻性肥厚型心肌病治疗的技术要点及研究进展[J]. 心电与循环, 2023, 42(4): 315-319. doi: 10.12124/j.issn.2095-3933.2023.4.2023-5580
[19]	Lafitte S, Reant P, Touche C, et al. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics[J]. J Am Coll Cardiol, 2013, 62(9): 842-850. doi: 10.1016/j.jacc.2013.06.007
[20]	Wu XP, Li YD, Wang YD, et al. Decreased biventricular mechanics and functional reserve in nonobstructive hypertrophic cardiomyopathy patients: implications for exercise capacity[J]. Int J Cardiovasc Imaging, 2019, 35(5): 869-879. doi: 10.1007/s10554-019-01530-y
[21]	Cardoso I, Viegas JM, Rosa SA, et al. Three-dimensional echocardiography for the evaluation of hypertrophic cardiomyopathy patients: relation to symptoms and exercise capacity[J]. Int J Cardiovasc Imaging, 2023, 39(12): 2475-2481. doi: 10.1007/s10554-023-02952-5
[22]	杨帆, 王静, 康楠, 等. 运动负荷超声心动图联合斑点追踪成像评估肥厚型心肌病患者右心功能的研究[J]. 临床心血管病杂志, 2022, 38(12): 934-940.
[23]	Wu XP, Li YD, Wang YD, et al. Impaired Right Ventricular Mechanics at Rest and During Exercise Are Associated With Exercise Capacity in Patients With Hypertrophic Cardiomyopathy[J]. J Am Heart Assoc, 2019, 8(5): e11269.
[24]	Efthimiadis GK, Giannakoulas G, Parcharidou DG, et al. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy[J]. Int J Cardiol, 2011, 153(2): 179-184. doi: 10.1016/j.ijcard.2010.08.026
[25]	Efthimiadis GK, Giannakoulas G, Parcharidou DG, et al. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy[J]. Int J Cardiol, 2011, 153(2): 179-184. doi: 10.1016/j.ijcard.2010.08.026
[26]	Wang J, Fang F, Yip GW, et al. Importance of chronotropic response and left ventricular long-axis function for exercise performance in patients with heart failure and preserved ejection fraction[J]. Int J Cardiol, 2016, 202: 339-343. doi: 10.1016/j.ijcard.2015.09.029
[27]	Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 1999, 33(7): 2044-2051. doi: 10.1016/S0735-1097(99)00094-7
[28]	MacNamara JP, Dias KA, Hearon CJ, et al. Limits to submaximal and maximal exercise in patients with hypertrophic cardiomyopathy[J]. J Appl Physiol(1985), 2022, 133(4): 787-797. doi: 10.1152/japplphysiol.00566.2021
[29]	Magri D, Santolamazza C. Cardiopulmonary Exercise Test in Hypertrophic Cardiomyopathy[J]. Ann Am Thorac Soc, 2017, 14(Supplement_1): S102-S109. doi: 10.1513/AnnalsATS.201611-884FR
[30]	Noureldin RA, Liu S, Nacif MS, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson, 2012, 14(1): 17. doi: 10.1186/1532-429X-14-19
[31]	Wang J, Yang S, Ma X, et al. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines[J]. Eur Heart J, 2023, 44(45): 4781-4792. doi: 10.1093/eurheartj/ehad581
[32]	Romero-Puche A, Marin F, Gonzalez-Carrillo J, et al. Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy[J]. Rev Esp Cardiol, 2008, 61(8): 853-860. doi: 10.1157/13124996
[33]	邱羽菲, 史嘉翊, 宋旭东, 等. 心肌纤维化的发生机制及治疗研究进展[J]. 心脏杂志, 2021, 33(5): 553-557.
[34]	冯晓玄, 冯颖青. 超声中心肌做功参数的正常参考值范围及临床应用研究进展[J]. 分子影像学杂志, 2022, 45(6): 957-966.
[35]	侯淑红, 林瑜芬, 吴波, 等. 左室压力-应变环定量评估肥厚型心肌病患者心肺运动试验前后左室功能变化[J]. 临床超声医学杂志, 2023, 25(11): 925-929. doi: 10.3969/j.issn.1008-6978.2023.11.017
[36]	曾银燕. 左室压力-应变环评估肥厚型心肌病患者心肌做功的应用研究[D]. 南昌大学, 2022.
[37]	黄曼芸, 黄晓红. 肥厚型心肌病患者二尖瓣病变的研究进展[J]. 中国分子心脏病学杂志, 2022, 22(1): 4501-4505.
[38]	Kampaktsis PN, Albert BJ, Kim J, et al. Impact of Mitral Regurgitation Severity and Cause on Effort Tolerance-Integrated Stress Myocardial Perfusion Imaging and Echocardiographic Assessment of Patients With Known or Suspected Coronary Artery Disease Undergoing Exercise Treadmill Testing[J]. J Am Heart Assoc, 2019, 8(5): e10974.
[39]	Uretsky S, Aldaia L, Marcoff L, et al. The relationship between mitral regurgitant severity, symptoms, and exercise capacity in primary degenerative mitral regurgitation[J]. Int J Cardiovasc Imaging, 2023, 39(9): 1677-1685. doi: 10.1007/s10554-023-02881-3
[40]	Malahfji M, Senapati A, Debs D, et al. Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy[J]. Sci Rep, 2020, 10(1): 15977. doi: 10.1038/s41598-020-71394-z
[41]	Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging[J]. Circulation, 2007, 115(18): 2418-2425.
[42]	Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population[J]. J Am Heart Assoc, 2014, 3(3): e1002.
[43]	Azarbal F, Singh M, Finocchiaro G, et al. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. Heart, 2014, 100(8): 624-630.
[44]	Konecny T, Kuniyoshi FH, Orban M, et al. Under-diagnosis of sleep apnea in patients after acute myocardial infarction[J]. J Am Coll Cardiol, 2010, 56(9): 742-743.
[45]	Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2013, 62(5): 449-457.
[46]	Larsen CM, Ball CA, Hebl VB, et al. Effect of Body Mass Index on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy[J]. Am J Cardiol, 2018, 121(1): 100-106.
[47]	Hernandez-Romero D, Jover E, Martinez CM, et al. TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy[J]. Eur J Clin Invest, 2015, 45(2): 179-186.
[48]	Roldan V, Marin F, Gimeno JR, et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy[J]. Am Heart J, 2008, 156(1): 85-91.
[49]	Lampert R, Ackerman MJ, Marino BS, et al. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy[J]. JAMA Cardiol, 2023, 8(6): 595-605.
[50]	Tafelmeier M, Baessler A, Wagner S, et al. Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy[J]. Clin Cardiol, 2020, 43(5): 430-440.
[51]	Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397(10293): 2467-2475.
[52]	Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy[J]. J Am Coll Cardiol, 2021, 78(25): 2505-2517.
[53]	Borisov KV. Surgery of Hypertrophic Obstructive Cardiomyopathy in Patients With Severe Hypertrophy, Myocardial Fibrosis, and Ventricular Tachycardia[J]. Ann Thorac Surg, 2018, 106(1): 30-37.
[54]	魏翔. 肥厚型梗阻性心肌病外科治疗进展[J]. 临床外科杂志, 2023, 31(9): 801-803.
[55]	Fang J, Liu Y, Zhu Y, et al. First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy[J]. J Am Coll Cardiol, 2023, 82(7): 575-586.
[56]	Liu L, Li J, Zuo L, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy[J]. J Am Coll Cardiol, 2018, 72(16): 1898-1909.
[57]	Li J, Zhang J, Shi Y, et al. Myocardial mechanics of percutaneous intramyocardial septal radiofrequency ablation[J]. Heart, 2023, 109(4): 289-296.